查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046210

體外診斷品管市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用途、地區、競爭對手分類，2021-2031年

In Vitro Diagnostics Quality Control Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End-use Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球體外診斷品管市場預計將從 2025 年的 11.6 億美元成長到 2031 年的 12.7 億美元，複合年成長率為 1.52%。

這些品管產品是檢驗診斷檢測系統準確性的重要穩定材料，從而確保患者獲得可靠的檢測結果。推動該市場發展的關鍵因素包括檢查室認證標準的日益嚴格執行以及需要頻繁監測的慢性病盛行率不斷上升。此外，獨立第三方品管樣品的日益普及有助於消除儀器偏差，這也推動了市場擴張，使其區別於一般的技術進步。

市場概覽
預測期 2027-2031
市場規模：2025年 11.6億美元
市場規模：2031年 12.7億美元
複合年成長率：2026-2031年 1.52%
成長最快的細分市場 品管
最大的市場 北美洲

市場成長的主要障礙是高昂的合規成本和複雜的法規結構，這尤其給小規模診斷機構的預算帶來了壓力。儘管面臨這些財務挑戰，但人們普遍認知到認證實踐的卓越性至關重要，這持續推動基本客群的擴大。例如，美國病理學家協會 (CAP) 在 2024 年認證了創紀錄的 657 家新檢查室，使全球整體認證實驗室總數達到 8,350 家。這一數字凸顯了即使在經濟受限的情況下，對品質保證產品的持續且迫切的需求仍然存在。

市場促進因素

慢性疾病和感染疾病率的上升是全球體外診斷（IVD）品管市場的重要驅動力，因為這必然導致患者檢體數量的增加。隨著癌症和糖尿病等疾病盛行率的上升，診斷機構必須處理更多樣本，因此定期使用品管樣本對於驗證儀器準確性和最大限度降低誤差率至關重要。疾病負擔與診斷檢測之間的這種直接聯繫在腫瘤學領域尤其明顯，在腫瘤學領域，準確的生物標記檢測對於制定有效的治療方案至關重要。美國癌症協會於2024年1月發布的《2024年癌症事實與數據》報告預測，美國新增癌症病例將達到2,001,140例，這凸顯了關鍵診斷檢測的巨大規模，而持續的品質保證至關重要。

嚴格的監管標準和獲得認證的臨床檢查室數量的增加，透過要求嚴格的合規程序，進一步推動了市場成長。認證機構制定了嚴格的指導方針，要求檢查室按指定的周期進行第三方監督，將品管從建議做法轉變為營運要求。隨著越來越多的機構尋求認證以確保報銷並維護自身聲譽，這種監管壓力正在擴大潛在基本客群。根據美國醫療保險和醫療補助服務中心 (CMS) 發布的 2024 年 3 月 CLIA檢查室統計數據更新，美國共有 15,894 家獲得認證的檢查室，佔受嚴格監管的最終用戶總數的很大一部分。 Bio-Rad Laboratories 於 2024 年 2 月發布的 2023 年第四季度和全年財務業績報告顯示，其臨床診斷部門的淨銷售額為 14.893 億美元，對品管和糖尿病相關產品的需求被認為是成長的驅動力，反映了這些合規性和銷售量因素對業務的影響。

市場挑戰

高昂的合規成本和複雜的法規結構是全球體外診斷（IVD）品管市場擴張的主要障礙。隨著監管機構實施更嚴格的認證標準以保障病人安全，診斷設備製造商和實驗室面臨與驗證、文件編制和員工培訓相關的不斷增加的營運成本。這種財務負擔在預算有限的小規模機構中尤為突出，迫使它們優先考慮基本的監管合規，而不是投資先進的品管系統。因此，資金被轉移到滿足基本要求上，減少了可用於創新和市場拓展的資金，最終阻礙了整個產業的發展。

近期一項關於監管環境變化相關成本的行業研究清楚地表明了這一經濟負擔的規模。 MedTech Europe在2024年發布的報告顯示，與先前的指令相比，新法規下診斷設備製造商的認證和維護成本增加了高達100%。這種非創收支出的大幅成長限制了企業投資新產品開發和進入新區域市場的能力，直接阻礙了其在全球市場的潛在收入成長。

市場趨勢

隨著臨床檢查室擴大將基因組分析整合到常規診斷流程中，次世代定序(NGS) 專用對照樣本的出現正在改變市場格局。與傳統的單分析物檢測不同，現代分子診斷需要高倍率的參考物質，能夠同時檢驗數百個突變靶點，以確保個人化醫療檢測的準確性。這種發展趨勢正促使製造商突破標準感染疾病對照樣本的限制，進軍生殖醫學等複雜的基因體學領域。在2024年8月LGC Clinical Diagnostics發布的題為「LGC Clinical Diagnostics推出Seraseq攜帶者篩檢DNA混合參考物質」的新聞稿中，該公司宣布推出一種新的參考物質，其中包含48個基因的54個具有臨床意義的突變，旨在支持高通量基因檢測的檢驗。

隨著檢查室不斷最佳化日常工作流程，力求最大限度地減少儀器驗證所需的試劑用量，包含多種分析物的整合式品控品的應用正日益普及。透過使用包含多種分析物的單一配方，診斷機構可以顯著縮短處理時間並降低儲存成本。這在當前全球實驗室技術人員短缺的情況下尤其重要。這種向效率提升型解決方案的營運轉變，顯然正成為市場領導者的重要收入來源。根據Bio-Rad Laboratories於2024年10月發布的2024年第三季財報，該公司臨床診斷部門的淨銷售額達到3.89億美元。這項業績主要得益於市場對品管產品的持續強勁需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球體外診斷品管市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（品管、資料管理解決方案、品質保證服務）
    • 依應用領域（免疫檢測、血液學、臨床化學、分子診斷、血液凝固檢驗、微生物學等）
    • 依最終用途（醫院/診所、門診手術中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美體外診斷品管市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲體外診斷品管市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區體外診斷品管市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲體外診斷品管市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲體外診斷品管市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球體外診斷品管市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd
  • Alere, Inc.
  • Abbott Laboratories Inc.
  • Hologic, Inc.
  • Qiagen NV
  • Bio-Rad Laboratories, Inc.
  • Quidel Corporation
  • bioMerieux, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 21664

The Global In Vitro Diagnostics Quality Control Market is projected to expand from USD 1.16 Billion in 2025 to USD 1.27 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 1.52%. These quality controls are stable materials essential for verifying the accuracy of diagnostic testing systems, thereby ensuring reliable patient outcomes. Key drivers for this market include the strict enforcement of laboratory accreditation standards and the growing prevalence of chronic diseases that necessitate frequent monitoring. Additionally, the increasing use of independent third-party controls, which help eliminate instrument bias, further supports market expansion, distinguishing it from general technological advancements.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.16 Billion
Market Size 2031USD 1.27 Billion
CAGR 2026-20311.52%
Fastest Growing SegmentQuality Controls
Largest MarketNorth America

A primary obstacle to market growth is the considerable cost of compliance coupled with complex regulatory frameworks, which particularly strain the budgets of smaller diagnostic facilities. Despite this financial challenge, the imperative for certified operational excellence continues to broaden the customer base. For instance, the College of American Pathologists accredited a record 657 new laboratories in 2024, bringing their global total to 8,350 facilities. This figure highlights the persistent and critical demand for quality assurance products, even amidst economic constraints.

Market Driver

The rising incidence of chronic and infectious diseases stands as a significant catalyst for the Global In Vitro Diagnostics Quality Control Market, as it inherently escalates the volume of patient testing. As the prevalence of conditions like cancer and diabetes increases, diagnostic facilities must manage higher sample throughputs, which mandates the regular use of quality control materials to confirm instrument precision and minimize error rates. This direct link between disease burden and diagnostic testing is clearly seen in oncology, where accurate biomarker testing is vital for effective treatment planning. The American Cancer Society's 'Cancer Facts & Figures 2024' report, published in January 2024, projected 2,001,140 new cancer diagnoses in the United States, underscoring the massive scale of critical diagnostics requiring continuous quality assurance.

The enforcement of stringent regulatory standards and the increasing number of accredited clinical laboratories further propel market growth by requiring rigorous compliance protocols. Accreditation bodies mandate strict guidelines that necessitate laboratories to perform third-party controls at scheduled intervals, thus transforming quality control from a recommended practice into an operational imperative. This regulatory pressure expands the potential customer base, as more facilities seek certification to secure reimbursement and maintain their reputation. According to the Centers for Medicare & Medicaid Services' 'CLIA Laboratory Statistical Update' from March 2024, 15,894 laboratories in the United States held a Certificate of Accreditation, representing a substantial segment of highly regulated end-users. Bio-Rad Laboratories' 'Fourth-Quarter and Full-Year 2023 Financial Results' in February 2024, which reported $1,489.3 million in net sales for its Clinical Diagnostics segment, specifically cited demand for quality control and diabetes-related products as a driver, reflecting the commercial impact of these compliance and volume factors.

Market Challenge

The high cost of compliance and the intricate nature of regulatory frameworks pose a substantial obstacle to the expansion of the global in vitro diagnostics quality control market. As governing bodies introduce more rigorous accreditation standards to safeguard patient safety, diagnostic manufacturers and laboratories face escalating operational expenditures related to validation, documentation, and staff training. This financial strain is particularly pronounced for smaller facilities operating with constrained budgets, compelling them to prioritize basic regulatory adherence over investing in advanced quality control systems. Consequently, the redirection of capital towards meeting mandatory requirements reduces funds available for innovation and market penetration, thereby impeding overall industry development.

The scale of this economic burden is clearly illustrated by recent industry findings concerning the costs associated with evolving regulatory landscapes. MedTech Europe reported in 2024 that certification and maintenance expenses for diagnostic manufacturers under new regulations have risen by up to 100 percent compared to previous directives. This considerable increase in non-revenue generating outlays restricts companies' capacity to invest in developing new products or entering new geographical markets, directly limiting the potential revenue growth of the global market.

Market Trends

The emergence of specialized controls for Next-Generation Sequencing (NGS) is significantly transforming the market as clinical laboratories progressively incorporate genomic profiling into routine diagnostic workflows. Unlike conventional single-analyte testing, modern molecular diagnostics demand highly multiplexed reference materials capable of simultaneously validating hundreds of variant targets to ensure the precision of personalized medicine assays. This evolution prompts manufacturers to innovate beyond standard infectious disease controls, venturing into complex genomic areas such as reproductive health. As reported by LGC Clinical Diagnostics in August 2024, their press release 'LGC Clinical Diagnostics Launches Seraseq Carrier Screening DNA Mix Reference Materials' announced a new reference material containing 54 clinically significant variants across 48 genes, designed to support the validation of high-throughput genetic assays.

The adoption of multi-analyte consolidated control materials is gaining momentum as laboratories seek to optimize daily workflows and minimize the volume of reagents needed for instrument validation. By utilizing single formulations that incorporate multiple analytes, diagnostic facilities can substantially reduce handling time and storage costs, which is a crucial benefit given the current global shortage of laboratory technicians. This operational shift towards efficiency-enhancing solutions is proving to be a significant revenue generator for established market leaders. Bio-Rad Laboratories' 'Q3 2024 Financial Results' report from October 2024 indicated that its Clinical Diagnostics segment achieved net sales of $389 million, a performance primarily driven by the sustained robust demand for its quality control products.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Alere, Inc.
  • Abbott Laboratories Inc.
  • Hologic, Inc.
  • Qiagen N.V.
  • Bio-Rad Laboratories, Inc.
  • Quidel Corporation
  • bioMerieux, Inc.
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.

Report Scope

In this report, the Global In Vitro Diagnostics Quality Control Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In Vitro Diagnostics Quality Control Market, By Type

  • Quality Controls
  • Data Management Solutions
  • Quality Assurance Services

In Vitro Diagnostics Quality Control Market, By Application

  • Immunoassay
  • Hematology
  • Clinical Chemistry
  • Molecular Diagnostics
  • Coagulation
  • Microbiology
  • Others

In Vitro Diagnostics Quality Control Market, By End-use

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

In Vitro Diagnostics Quality Control Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In Vitro Diagnostics Quality Control Market.

Available Customizations:

Global In Vitro Diagnostics Quality Control Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global In Vitro Diagnostics Quality Control Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Quality Controls, Data Management Solutions, Quality Assurance Services)
    • 5.2.2. By Application (Immunoassay, Hematology, Clinical Chemistry, Molecular Diagnostics, Coagulation, Microbiology, Others)
    • 5.2.3. By End-use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America In Vitro Diagnostics Quality Control Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End-use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States In Vitro Diagnostics Quality Control Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-use
    • 6.3.2. Canada In Vitro Diagnostics Quality Control Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-use
    • 6.3.3. Mexico In Vitro Diagnostics Quality Control Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-use

7. Europe In Vitro Diagnostics Quality Control Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End-use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany In Vitro Diagnostics Quality Control Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-use
    • 7.3.2. France In Vitro Diagnostics Quality Control Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-use
    • 7.3.3. United Kingdom In Vitro Diagnostics Quality Control Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-use
    • 7.3.4. Italy In Vitro Diagnostics Quality Control Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-use
    • 7.3.5. Spain In Vitro Diagnostics Quality Control Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-use

8. Asia Pacific In Vitro Diagnostics Quality Control Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China In Vitro Diagnostics Quality Control Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-use
    • 8.3.2. India In Vitro Diagnostics Quality Control Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-use
    • 8.3.3. Japan In Vitro Diagnostics Quality Control Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-use
    • 8.3.4. South Korea In Vitro Diagnostics Quality Control Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-use
    • 8.3.5. Australia In Vitro Diagnostics Quality Control Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-use

9. Middle East & Africa In Vitro Diagnostics Quality Control Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End-use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia In Vitro Diagnostics Quality Control Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-use
    • 9.3.2. UAE In Vitro Diagnostics Quality Control Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-use
    • 9.3.3. South Africa In Vitro Diagnostics Quality Control Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-use

10. South America In Vitro Diagnostics Quality Control Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End-use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil In Vitro Diagnostics Quality Control Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-use
    • 10.3.2. Colombia In Vitro Diagnostics Quality Control Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-use
    • 10.3.3. Argentina In Vitro Diagnostics Quality Control Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global In Vitro Diagnostics Quality Control Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Alere, Inc.
  • 15.3. Abbott Laboratories Inc.
  • 15.4. Hologic, Inc.
  • 15.5. Qiagen N.V.
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. Quidel Corporation
  • 15.8. bioMerieux, Inc.
  • 15.9. Sysmex Corporation
  • 15.10. Thermo Fisher Scientific, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer